6533b85afe1ef96bd12b8e46
RESEARCH PRODUCT
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes
Ilenia PepeSalvatore Di RosaGerald H. TomkinRizzo ManfrediAngelo Maria PattiGaetana Di FedeGiovam Battista RiniMaria Rosa Valeriosubject
medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentType 2 diabetesmedicine.diseaseMetformindiabetes LDL size prevention small dense LDL therapyEndocrinologyInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)PrediabetesCardiology and Cardiovascular MedicinebusinessPioglitazoneDyslipidemiamedicine.drugLipoproteindescription
Type 2 diabetes is associated with a cluster of inter-related plasma lipid and lipoprotein abnormalities, including reduced HDL-C, a predominance of small, dense LDL and elevated triglycerides. These abnormalities occur even in prediabetes, before blood sugars rise sufficiently in order to confirm a diagnosis of diabetes, and this transition phase incurs important cardiovascular risk. This is the rationale for paying attention to dyslipidemia through the use of the hypolipidemic, rather than hypoglycemic drugs only. A literature search (by Medline and Scopus) was performed. The authors also manually reviewed the references of selected articles for any pertinent material. Beyond the ‘quantity’ of LDL, several lipid-lowering agents and particularly statins, are only in part beneficial on the ‘quality’ of LDL, so that their net effect on small, dense LDL is moderate. Among hypoglycemic agents, insulin and metformin have shown a limited role on small, dense LDL, while pioglitazone is more beneficial. The effi...
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-10-01 | Clinical Lipidology |